MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition

16Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

Pharmacological inhibition of KRAS>RAF>MEK1/2>ERK1/2 signaling has provided no clinical benefit to patients with pancreatic ductal adenocarcinoma (PDAC). Interestingly, combined inhibition of MEK1/2 (with trametinib [T]) plus autophagy (with chloroquine [CQ] or hydroxychloroquine [HCQ]) demonstrated striking anti-tumor effects in preclinical models and in a patient (Patient 1). However, not all patients respond to the T/HCQ regimen, and Patient 1 eventually developed resistant disease. Here we report that primary or acquired resistance is associated with focal DNA copy number gains encompassing c-MYC. Furthermore, ectopic expression of c-MYC in PDAC cell lines rendered them T/HCQ resistant. Interestingly, a CDK4/6 inhibitor, palbociclib (P), also induced autophagy and overrode c-MYC–mediated T/HCQ resistance, such that P/HCQ promoted regression of T/HCQ-resistant PDAC tumors with elevated c-MYC expression. Finally, P/HCQ treatment of Patient 1 resulted in a biochemical disease response. These data suggest that elevated c-MYC expression is both a marker and a mediator of T/HCQ resistance, which may be overcome by the use of P/HCQ.

References Powered by Scopus

The hallmarks of cancer

24266Citations
N/AReaders
Get full text

AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1

5691Citations
N/AReaders
Get full text

Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the united states

5505Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Unraveling the interplay between RAS/RAF/MEK/ERK signaling pathway and autophagy in cancer: From molecular mechanisms to targeted therapy

20Citations
N/AReaders
Get full text

Combinatorial strategies to target RAS-driven cancers

19Citations
N/AReaders
Get full text

ASCL1-mediated ferroptosis resistance enhances the progress of castration-resistant prostate cancer to neurosecretory prostate cancer

13Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Silvis, M. R., Silva, D., Rohweder, R., Schuman, S., Gudipaty, S., Truong, A., … Kinsey, C. (2023). MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition. Journal of Experimental Medicine, 220(3). https://doi.org/10.1084/jem.20221524

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 6

67%

Researcher 3

33%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 6

55%

Medicine and Dentistry 3

27%

Pharmacology, Toxicology and Pharmaceut... 1

9%

Computer Science 1

9%

Article Metrics

Tooltip
Mentions
News Mentions: 2
Social Media
Shares, Likes & Comments: 59

Save time finding and organizing research with Mendeley

Sign up for free